OCUP News and Press, Ocuphire Pharma Inc Com From 09/15/22

FARMINGTON HILLS, Mich., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that Mina So...

Ocuphire Pharma ( NASDAQ: OCUP ), a clinical-stage biopharma company focused on eye diseases, announced Monday that the FDA granted a waiver in connection with the Prescription Drug User Fee Act (PDUFA) fee of $3.1M for its New Drug Application (NDA) for ophthalmic solution Ny...

FARMINGTON HILLS, Mich., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that the U.S...

Ocuphire Pharma ( NASDAQ: OCUP ) said on Thursday the last patient of the 103 enrolled subjects had completed their 24-week study visit in the Phase 2b trial of oral APX3330 for the treatment of diabetic retinopathy. The company said top-line results from the trial are...

Top-line Results are Expected in 4Q 2022 Interim Masked Safety Results Seen Demonstrate Favorable Safety and Tolerability Profile, Consistent with 11 Prior Trials of APX3330 Oral APX3330 has the Potential to Serve a Market of More Than 8 Million Diabetic Retinopathy Patien...

FARMINGTON HILLS, Mich., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that Mina So...

Ocuphire Pharma press release ( NASDAQ: OCUP ): Q2 GAAP EPS of -$0.25 beats by $0.08 . As of June 30, 2022, Ocuphire had cash and cash equivalents of approximately $17.0 million. Based on current projections, management believes the current cash on hand will be suf...

Completed Final Clinical Trials and Pre-NDA FDA Meeting to Support Registration of Nyxol in Reversal of Mydriasis (RM), On Track for Late 2022 NDA Submission and Potential 2023 Approval Positive Results from Phase 3 LYNX-1 Trial of Nyxol in Night Vision Disturbances (NVD) Mark S...

Canaccord Genuity 42 nd Annual Growth Conference on August 10, 2022 H.C. Wainwright 2 nd Annual Ophthalmology Virtual Conference on August 17, 2022, including a Fireside Panel with OCUP “Front of the Eye Progress and Flying Under the Radar” ...

Ophthalmology-focused Ocuphire Pharma ( NASDAQ: OCUP ) announced on Wednesday the issuance of a new U.S. patent for its lead candidate Nyxol eye drops that could extend the IP rights for the eye disease candidate. Nyxol is a once-daily, eye drop formulation of phentolamine...